Back to today’s briefing

Story perspectives

Gene Therapy Market to Surge to $51.55 Billion by 2032

1/17/2025

24 3

Summary

Gene Therapy Boom

The global gene therapy market is set to soar from around USD 10.93 billion in 2024 to an impressive USD 51.55 billion by 2032, fueled by a robust 21.4% growth rate. This surge is driven by increasing genetic disorders, groundbreaking technological innovations, and supportive regulations, with industry giants like Novartis, Biogen, and Gilead Sciences leading the charge.

Summary

Asia-Pacific QC Surge

The Asia-Pacific cell and gene therapy manufacturing QC market is on a remarkable growth trajectory, soaring from $246.4 million in 2023 to an anticipated $1.31 billion by 2033, fueled by an impressive 18.36% CAGR. This surge is driven by the rising adoption of CAR T-cells, rigorous regulations, and cutting-edge QC technologies such as AI-driven analytics and next-generation sequencing.

History

Historical Context

The gene therapy market's rapid growth mirrors the biotechnology boom of the late 1990s, driven by technological advances and increased investment. Companies like Novartis and Gilead, emerging from that era, now lead innovations, echoing past trends where breakthroughs transformed healthcare and fueled industry expansion.

1 of 3

Gene Therapy Boom

The global gene therapy market is set to soar from around USD 10.93 billion in 2024 to an impressive USD 51.55 billion by 2032, fueled by a robust 21.4% growth rate. This surge is driven by increasing genetic disorders, groundbreaking technological innovations, and supportive regulations, with industry giants like Novartis, Biogen, and Gilead Sciences leading the charge.

1 / 3